Cargando…
Current Photoactive Molecules for Targeted Therapy of Triple-Negative Breast Cancer
Cancer is the second leading cause of death worldwide; therefore, there is an urgent need to find safe and effective therapies. Triple-negative breast cancer (TNBC) is diagnosed in ca. 15–20% of BC and is extremely aggressive resulting in reduced survival rate, which is mainly due to the low therape...
Autores principales: | Dias, Cristina J., Helguero, Luisa, Faustino, Maria Amparo F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709347/ https://www.ncbi.nlm.nih.gov/pubmed/34946732 http://dx.doi.org/10.3390/molecules26247654 |
Ejemplares similares
-
Revisiting Current Photoactive Materials for Antimicrobial Photodynamic Therapy
por: Q. Mesquita, Mariana, et al.
Publicado: (2018) -
Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher, Brett, et al.
Publicado: (2016) -
Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant
por: Simon, Marisa, et al.
Publicado: (2017) -
Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer
por: Wei, Heng, et al.
Publicado: (2020) -
Triple-negative breast cancer and the potential for targeted therapy
por: Jhan, Jing-Ru, et al.
Publicado: (2017)